IQOS Smoking Room at Manila International Airport

Tajikistan is preparing legislation that could impose a nationwide ban on e-cigarettes. Upper house chair Rustami Emomali (Рустами Эмомали) has ordered the drafting of a bill, which is still under development. Retailers have begun scaling back sales amid tightening signals, while existing tobacco-control rules already restrict smoking in many public places and set fines.

Law360 reports that a Fifth Circuit panel expressed skepticism about the FDA’s claim that it has no de facto ban on flavored refillable e-cigarette products, noting that only six applications had been approved out of hundreds of thousands and that near-100% denials look like a ban.

IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.

New Zealand vape retailer Shosha is accused of using hidden, white-on-white text on its website to promote refillable and disposable vapes. A Health Ministry spokesperson said it could not comment on individual businesses’ compliance status while matters are being assessed, and said the ministry continues to monitor digital advertising and promotional activity and will act where it considers there may be a breach.

Azerbaijan has approved amendments to its tobacco law that introduce a comprehensive ban on e-cigarettes and their components, covering import, export, production, storage, wholesale and retail sales, and use. Nicotine-containing e-cigarettes are classified as tobacco products under the revised framework. The law takes effect on April 1, 2026.

FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.